JPMorgan Analysts Signal Bullish Outlook for Apellis Pharmaceuticals Following Strategic Market Review
Investment analysts at JPMorgan have recently shifted their stance on the biopharmaceutical sector, highlighting Apellis Pharmaceuticals as a primary beneficiary of current
by 
Josh Weiner
Josh Weiner